In this Quick Take volume, we discuss a recent trial that showed a doubled risk of relapse in patients with schizophrenia when antipsychotic medication was reduced. We also touch on the use of psilocybin for treatment-resistant depression, which sounds promising still, the need for concurrent psychotherapy and the potential long-term safety risks must be considered. Additionally, we talk about using famotidine for COVID-19 induced brain fog, real-world evidence supporting long-acting injectable antipsychotics for bipolar disorder, and effective management of poststroke depression.
- Provider:Medical Academy, LLC
- Activity Link: https://psychopharmacologyinstitute.com/publication/quick-take-vol-62-2801?utm_source=PARS+ACCME&utm_medium=PARS+ACCME&utm_campaign=PARS+ACCME
- Start Date: 2024-05-01 05:00:00
- End Date: 2024-05-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Performance
- Provider Ship: Jointly Provided
- Registration: Limited
Subscribe
Login
0 Comments
Oldest